US EditionRFK Jr. weighs options for Medicare, Medicaid coverage of GLP-1 medications
- The Trump administration plans to rescind a Biden proposal regarding anti-obesity medications for Medicare and Medicaid recipients.
- The Biden plan aimed to broaden coverage for drugs like Ozempic and Wegovy, known as GLP-1 inhibitors, regardless of cardiovascular disease.
- These GLP-1 drugs, initially for Type 2 diabetes, gained popularity for weight management but carry significant out-of-pocket costs for patients.
- Secretary Kennedy, in October 2024, stated, "They're counting on selling it to Americans because we're so stupid and so addicted to drugs."
- Kennedy is debating a framework, open to GLP-1 medications if other interventions fail, while a study links Ozempic/Wegovy to potential blindness.
13 Articles
13 Articles
John Curley backs RFK Jr.'s SNAP proposal: 'Stop funding junk food'
A new proposal from Health Secretary Robert F. Kennedy Jr. could block Supplemental Nutrition Assistance Program (SNAP) recipients from using benefits to buy junk food. RFK Jr. said that not only would the policy keep Americans healthy, but it could also reduce taxpayer spending. John Curley, co-host of “The John Curley Show”, agreed with RFK Jr. during an episode earlier this week. “We have a fattening American population, a sick American popul…
Commentary: New drug price controls, same old consequences
The government recently announced a new batch of drugs — including blockbuster weight-loss treatment Wegovy and prostate cancer therapy Xtandi — that will face price controls under the Inflation Reduction Act. These price controls won’t result in more affordable and accessible medicines. They’ll stifle the development of lifesaving drugs while inflating healthcare costs. It’s up to the administration and Congress to prevent this damage — by rol…
RFK Jr. weighs options for Medicare, Medicaid coverage of GLP-1 medications
Health and Human Services Secretary Robert F. Kennedy Jr. said that the Trump administration is considering a framework for GLP-1 medications to treat obesity.Recently, the Trump administration announced it would rescind a Biden administration proposal to expand coverage of anti-obesity medications such as Ozempic and Wegovy for Medicare and Medicaid recipients. Currently, Medicare and most state Medicaid programs only cover these drugs for indi…
Weight-loss drugs like Ozempic are changing how Americans eat
A new study led by researchers at the Arkansas Agricultural Experiment Station has found that the popular class of weight-loss drugs known as GLP-1 agonists—including Mounjaro, Ozempic, and Wegovy—is reshaping the way people eat. As more Americans use these medications, their food preferences and eating habits are shifting significantly, prompting food and beverage companies to […] The post Weight-loss drugs like Ozempic are changing how America…
Coverage Details
Bias Distribution
- 80% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
